These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30543542)

  • 1. COMPASS for Vascular Surgeons: Practical Considerations.
    Hussain MA; Wheatcroft M; Nault P; Lindsay TF; Bhatt DL; Anand SS; Verma S; Al-Omran M
    Curr Opin Cardiol; 2019 Mar; 34(2):178-184. PubMed ID: 30543542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.
    Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S
    J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
    Kaplovitch E; Eikelboom JW; Dyal L; Aboyans V; Abola MT; Verhamme P; Avezum A; Fox KAA; Berkowitz SD; Bangdiwala SI; Yusuf S; Anand SS
    JAMA Cardiol; 2021 Jan; 6(1):21-29. PubMed ID: 32997098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
    Lapébie FX; Aboyans V; Lacroix P; Constans J; Boulon C; Messas E; Ferrières J; Bongard V; Bura-Rivière A
    Eur J Vasc Endovasc Surg; 2021 Sep; 62(3):439-449. PubMed ID: 34330647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS.
    Bhagirath VC; Eikelboom JW; Anand SS
    Future Cardiol; 2018 Nov; 14(6):443-453. PubMed ID: 30417662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
    Anand SS; Hiatt W; Dyal L; Bauersachs R; Berkowitz SD; Branch KRH; Debus S; Fox KAA; Liang Y; Muehlhofer E; Nehler M; Haskell LP; Patel M; Szarek M; Yusuf S; Eikelboom J; Bonaca MP
    Eur J Prev Cardiol; 2022 May; 29(5):e181-e189. PubMed ID: 34463737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
    Capell WH; Bonaca MP; Nehler MR; Chen E; Kittelson JM; Anand SS; Berkowitz SD; Debus ES; Fanelli F; Haskell L; Patel MR; Bauersachs R; Hiatt WR
    Am Heart J; 2018 May; 199():83-91. PubMed ID: 29754671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban in Peripheral Artery Disease after Revascularization.
    Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
    N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
    Coppens M; Weitz JI; Eikelboom JWA
    Circ Res; 2019 Feb; 124(3):416-425. PubMed ID: 30702997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial.
    Tsilimigras DI; Moris D; Karaolanis G; Kakkos SK; Filis K; Sigala F
    Curr Pharm Des; 2018; 24(38):4516-4517. PubMed ID: 30621559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?
    Kruger PC; Guzik TJ; Eikelboom JW
    Kardiol Pol; 2019 Aug; 77(7-8):661-669. PubMed ID: 31144674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
    Branch KR; Probstfield JL; Eikelboom JW; Bosch J; Maggioni AP; Cheng RK; Bhatt DL; Avezum A; Fox KAA; Connolly SJ; Shestakovska O; Yusuf S
    Circulation; 2019 Aug; 140(7):529-537. PubMed ID: 31163978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease.
    Wheeler M; Chan N; Eikelboom J
    Future Cardiol; 2020 Nov; 16(6):597-611. PubMed ID: 32633570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease.
    Coleman CI; Kharat AA; Bookhart B; Baker WL
    Curr Med Res Opin; 2022 Jan; 38(1):27-34. PubMed ID: 34641745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios.
    McClure GR; Kaplovitch E; Narula S; Bhagirath VC; Anand SS
    Curr Cardiol Rep; 2019 Aug; 21(10):115. PubMed ID: 31471666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study.
    Lamy A; Eikelboom J; Sheth T; Connolly S; Bosch J; Fox KAA; Zhu J; Lonn E; Dagenais G; Widimsky P; Branch KRH; Bhatt DL; Zheng Z; Straka Z; Dagenais F; Kong Y; Marsden T; Lee SF; Copland I; Yusuf S
    J Am Coll Cardiol; 2019 Jan; 73(2):121-130. PubMed ID: 30654882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both.
    Fox KAA; Anand SS; Aboyans V; Cowie MR; Debus ES; Zeymer U; Monje D; Vogtländer K; Lawatscheck R; Gay A
    Am Heart J; 2020 Apr; 222():166-173. PubMed ID: 32092505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.
    Bhatt DL; Eikelboom JW; Connolly SJ; Steg PG; Anand SS; Verma S; Branch KRH; Probstfield J; Bosch J; Shestakovska O; Szarek M; Maggioni AP; Widimský P; Avezum A; Diaz R; Lewis BS; Berkowitz SD; Fox KAA; Ryden L; Yusuf S;
    Circulation; 2020 Jun; 141(23):1841-1854. PubMed ID: 32223318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
    Krantz MJ; Debus SE; Hsia J; Patel MR; Anand SS; Nehler MR; Hess CN; Capell WH; Bracken T; Szarek M; Mátyás L; Krievins DK; Nault P; Stefanov S; Haskell LP; Berkowitz SD; Muehlhofer E; Hiatt WR; Bauersachs RM; Bonaca MP
    Eur Heart J; 2021 Oct; 42(39):4040-4048. PubMed ID: 34430972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation.
    Rivera-Caravaca JM; Camelo-Castillo A; Ramírez-Macías I; Gil-Pérez P; López-García C; Esteve-Pastor MA; Orenes-Piñero E; Tello-Montoliu A; Marín F
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.